First Shanghai to give Sinopharm holding target price of 43 yuan cibi

Shanghai: first give Sinopharm target price of 43 yuan a thousand thousand shares hot column capital flows on stock diagnosis the latest rating simulated trading client sina finance App: Live on-line blogger to tutor Sina Hong Kong APP: real time market exclusive reference stocks also worth the investment? What’s the problem? Where is the future of the way out? Sina launched the "Hong Kong Hong Kong stocks as well as unattractive" discussion, with a rational and constructive attitude, welcome attention to Hong Kong stocks, concern of the capital market, Hong Kong stocks together for suggestions, seek the Hong Kong stock market tomorrow. Please to hkstock_biz@sina. Sinopharm (01099) in August to a record high of 42.5 yuan after repeated adjustments for two months in rose after the consolidation phase, and has high quality pharmaceutical stocks to absorb long-term value, that will still be funds to attract attention, suggestions can absorb the chance when low. In fact, the Chinese medicine to maintain good business performance, the first half net profit attributable to shareholders of 2 billion 529 million yuan, year-on-year growth of 32.15%. The main Chinese medicine distribution business affected by the price impact is less, plus the state-owned stock index, is expected to get the funds into the interior of a plate extrusion. In addition, the city has risen to a high level of the situation in the stage, I believe that the long-term value of the leading pharmaceutical stocks, will continue to be one of the objectives of the funds to follow up. Proposal can wait for the stock price back to 38 yuan to gradually take advantage of low absorption, stop at $34, the target to see 43 yuan. (both) to enter the Sina financial stocks] discussion相关的主题文章: